||Registry of biomedical companies:
  [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [Z] 501 active entries
Heidelberg, 69115, Germany
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
BIOPHARM GmbH - SYMBIOSIS part of BIOPHARM
SYMBIOSIS - The Analytical Company - is the newly created business division of Biopharm GmbH offering services and solutions for biopharmaceuticals and classical pharmaceuticals. SYMBIOSIS integrates the extensive experience and expertise of more than 26 years of BIOPHARM in analytical services combined with a customer-focused approach driven by excellence in process, communication and quality. For more information please visit www.symbiosis.de.
With more than 25 years experience BIOPHARM is a well-known innovator in the field of human growth factors for Regenerative Medicine. With our Growth Factor Platform Technology offering versatile applications and two major license deals in place (Phase I/II and Phase III) BIOPHARM has proven its unique market position and strong innovation pipeline. In addition, Biopharm offers you a wide range of methods for a successful development of your product. Our developmental services cover the entire biotechnological chain from gene to protein including biosimilars and biobetters.
BIOPHARM’s Growth Factor Technology Platform offers new opportunities using tailor made drug design with significant advantages over existing growth factors on the market
Unique technology platform dedicated to medical applications.
Due to the gentle processing, this technology allows the combination of sensitive biopolymers and active pharmaceuticals such as growth factors (small molecules, recombinant proteins etc.) by incorporating them in a single process step into biodegradable nonwoven delivery systems. This delivery technology offers new opportunities for advanced active wound care, cartilage and bone repair.
Regenerative Medicine Proprietary growth factor technology platform – Drug Delivery - Drug device combinations to develop intelligent biomaterials - Biomarkers
Traumatic wounds can be counteracted by new products based on biological components. The most recent results from Biopharm have demonstrated that our products have significant positive effects on the granualtion and epithelisation phase of the wound healing process as well on the structural composition of the skin. These structural improvements are due to increased wound healing and deposition of proteins (collagens, elastin) and of the proteoglycan decorin.
Bone & Cartilage Regeneration (Orthopaedics):
Biopharm's proprietary growth facto technology induces and promotes osteoplastic and chondrogenic properties. Potential fields of application are all repair interventions of the musculoskeltal system especially healing of bone fractures and cartilage repair.
Partnering strategy / collaborations:As one of the pioneers in the development of recombinant human growth factors we invite clients who are interested in the development and testing of innovative pharmaceuticals and biopharmaceuticals and who are looking for a highly experienced and specialized team of scientists.
Existing licence partners of our Growth factor technology platform are
- Advanced Technologies and Regenerative Medicine, LLC (a subsidiary of the Johnson & Johnson Group), in Phase I/II
- SCIL Technology GmbH, an innovative biotech company based in Munich that has signed a sublicense contract with MEDTRONIC, Inc., in Phase III
Last update of this entry: October 04, 2012